Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Feasibility of TA-CIN Vaccine in HPV16 Associated Cervical Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02405221
Recruitment Status : Recruiting
First Posted : April 1, 2015
Last Update Posted : May 8, 2019
Sponsor:
Collaborators:
National Cancer Institute (NCI)
PapiVax Biotech, Inc.
Information provided by (Responsible Party):
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Brief Summary:
This study will be looking at what dose of the TA-CIN vaccine is safe and effective in patients with a history of HPV16-associated cervical cancer.

Condition or disease Intervention/treatment Phase
HPV16 Associated Cervical Cancer Biological: TA-CIN (arm) Biological: TA-CIN (thigh) Phase 1

Detailed Description:

This is a randomized, multi-center, open label pilot study. The primary goal of this study is to determine the safety of TA-CIN vaccine as adjuvant therapy, and to assess evidence of induction of HPV antigen-specific immunologic response when administered at different locations (arm or thigh). In this pilot study, a single dose level (100µg) assessment of the safety and tolerability of administering TA-CIN vaccine three times to either the arm versus the thigh of patients who have previously been treated for HPV16-related cervical cancer in the past year and are documented to have no evidence of disease recurrence based on standard-of-care imaging and/or clinical assessment upon eligibility.

A total of 14 patients will be enrolled to assess the safety of TA-CIN vaccine via different injection sites as adjuvant therapy. Safety assessments will continue for a period for 1 month after the last vaccination. Few or no serious adverse events (SAEs) are expected from this regimen and routes of administration. The motivation for the design is to confirm that the dose and site of injection implemented here has minimal or no systemic toxicity, as well as determining the preferred injection site that can elicit more potent immune response.

The study will consist of the following parts:

  • Screening evaluation
  • Dosing period and response assessments
  • Follow-up visits after last dose

Screening Evaluation:

The screening visit will be performed within 60 days of the first study drug administration visit. The study team will check the results of these screening tests to see if patient qualifies to participate.

Dosing Period:

Those who meet the study requirements during the screening period will then begin the dosing phase of this study. TA-CIN will be given as a single intramuscular injection every 4 weeks for a maximum of 3 times. The location of the injection (arm or thigh) will depend on randomization. Patients will be assessed for safety and response to treatment during this period.

Follow-Up Period:

Four follow-up evaluations will be performed during a clinic visit after the last dose of the vaccine. These will take place at the following time points: (1) 1-3 weeks after the last dose of the study drug, (2) about 6 months after the last dose of the study drug, (3) about 12 months after the last dose of the study drug, and (4) about 24 months after the last dose of the study drug.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 14 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Clinical Trial Assessing the Safety and Feasibility of Intramuscular Administration of the TA-CIN Vaccine as Adjuvant Therapy for Patients With History of HPV16 Associated Cervical Cancer
Actual Study Start Date : April 4, 2019
Estimated Primary Completion Date : November 2020
Estimated Study Completion Date : November 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cervical Cancer

Arm Intervention/treatment
Experimental: TA-CIN administration via thigh
Each dose of TA-CIN vaccine is fixed, 100µg. Patients will receive 3 doses of the TA-CIN 4 weeks apart (Weeks 1, 5, and 9), administered in the thigh. Patients will be followed for 2 years after the 1st dose is given.
Biological: TA-CIN (thigh)
TA-CIN vaccine 100µg IM in the arm at Week 1, 5, and 9.
Other Name: Tissue Antigen - Cervical Intraepithelial Neoplasia

Experimental: TA-CIN administration via arm
Each dose of TA-CIN vaccine is fixed, 100µg. Patients will receive 3 doses of the TA-CIN 4 weeks apart (Weeks 1, 5, and 9), administered in the arm. Patients will be followed for 2 years after the 1st dose is given.
Biological: TA-CIN (arm)
TA-CIN vaccine 100µg IM in the arm at Week 1, 5, and 9.
Other Name: Tissue Antigen - Cervical Intraepithelial Neoplasia




Primary Outcome Measures :
  1. Safety and feasibility as assessed by Number of Participants with treatment-related Adverse Events [ Time Frame: 4 years ]
    Safety and feasibility of intramuscular TA-CIN vaccine via arm or thigh as assessed by number of participants with with a history of HPV16 associated IB1-IV cervical cancer experiencing treatment-emergent adverse events as defined by CTCAE v4.0.


Secondary Outcome Measures :
  1. Antibody Response as measured by level of circulating antibody in peripheral blood [ Time Frame: up to 4 years ]
    Level of circulating antibody to HPV16 E6, E7, and L2 in the peripheral blood pre- and post-vaccination (visualized by ELISA).

  2. T-Cell Response as measured by level of circulating T-cells in peripheral blood [ Time Frame: up to 4 years ]
    Level of circulating HPV16 E6- and E7- specific CD8+ T cells and/or CD4+ T cells in the peripheral blood pre- and post-vaccination (visualized by ELISPOT)

  3. Mononucleocyte Response [ Time Frame: up to 4 years ]
    Proliferative responses of peripheral blood mononucleocytes pre- and post-vaccination in response to stimulation by HPV16 E6, E7 and L2


Other Outcome Measures:
  1. Circulating HPV16 E6-/E7-specific CD8+ T cells [ Time Frame: up to 4 years ]
    Levels of circulating HPV16 E6- and E7-specific CD8+ T cells in the peripheral blood pre- and post-vaccination (measured using T-cell receptor sequencing)

  2. Levels of HPV-specific neutralizing antibodies [ Time Frame: up to 4 years ]
    Levels of HPV-specific neutralizing antibodies in the peripheral blood pre- and post-vaccination

  3. Residual HPV16 Viral Load [ Time Frame: 4 years ]
    Residual HPV16 viral load in plasma

  4. Clinical Response as measured by Time to Disease Recurrence [ Time Frame: 4 years ]
    Clinical response associated with vaccine induced immune responses as measured by Time from administration of TA-CIN to disease recurrence.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 100 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients with HPV16 related stage IB1-IV cervical cancer who completed definitive treatment within 12 months
  2. Patients with no evidence of disease recurrence within 8 weeks of enrollment
  3. Documented to have HPV16 nucleic acid within the cervical tumor specimen as determined by in situ hybridization
  4. Fresh-frozen or paraffin-embedded material must be available for in situ hybridization testing for HPV16 nucleic acid for central confirmation
  5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1
  6. Adequate organ function as defined by study-specified laboratory tests
  7. Ability to understand and willingness to sign a written informed consent document
  8. Willing and able to comply with study schedule and other protocol requirements

Exclusion Criteria:

  1. Currently have or have history of certain study-specified heart, liver, kidney, lung, neurological, immune or other medical conditions
  2. Patients with a diagnosis of immunosuppression or prolonged, active use of immunosuppressive agents such as systemic steroids
  3. Prior HPV vaccination
  4. Had surgery, chemotherapy, or radiation therapy within 28 days prior to receiving study drug
  5. Another investigational product within 28 days prior to receiving study drug
  6. Active or chronic HIV, HBV, or HCV infection
  7. Pregnant or lactating
  8. Patients who have an active autoimmune disease
  9. Patients with a recognized immunodeficiency disease or are being chronically treated with immunosuppressive drugs
  10. Women of childbearing potential
  11. Patients with non-healed wounds
  12. A history of current or recent concurrent malignancy (≤5 years) except basal cell cancer.
  13. Inability to understand or unwillingness to sign an informed consent document

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02405221


Contacts
Layout table for location contacts
Contact: Amanda Nickles Fader, MD 410-955-8240 afader1@jhmi.edu
Contact: Richard Roden, PhD 410-955-8804 jhcccro@jhmi.edu

Locations
Layout table for location information
United States, Alabama
Women & Infants Center, University of Alabama at Birmingham Recruiting
Birmingham, Alabama, United States, 35233
Contact: Anna Wilbanks, MSN, RN, WHNP-BC    205-934-6454    asb2013@uab.edu   
Contact: Nuzhat R Siddiqui, MD, MS, CCRP    205-975-2618    nuzhat@uab.edu   
Principal Investigator: Charles A Leath, III, MD         
United States, Maryland
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Recruiting
Baltimore, Maryland, United States, 21287
Contact: Amy Deery, RN, BSN, OCN    410-614-1361    HopkinsBreastTrials@jhmi.edu   
Contact: Amanda Nickles Fader, MD    410-955-8240    afader1@jhmi.edu   
Principal Investigator: Amanda Nickles Fader, MD         
Sponsors and Collaborators
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI)
PapiVax Biotech, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Amanda Nickles Fader, MD Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Layout table for additonal information
Responsible Party: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
ClinicalTrials.gov Identifier: NCT02405221     History of Changes
Other Study ID Numbers: J1553
IRB00054202 ( Other Identifier: JHMIRB )
P50CA098252 ( U.S. NIH Grant/Contract )
First Posted: April 1, 2015    Key Record Dates
Last Update Posted: May 8, 2019
Last Verified: May 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins:
HPV
HPV16
Cervical Cancer
TA-CIN
Vaccine
Adjuvant
Nickles FaderPI
Additional relevant MeSH terms:
Layout table for MeSH terms
Uterine Cervical Diseases
Vaccines
Uterine Cervical Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Uterine Diseases
Genital Diseases, Female
Immunologic Factors
Physiological Effects of Drugs